Tag: insightec

[Insightec in PR Newswire] Insightec’s focused ultrasound for essential tremor study results demonstrated sustained and significant tremor improvement maintained out to 5 years

HAIFA, Israel and MIAMI, Nov. 7, 2022 /PRNewswire/ — Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced the publication of the largest prospective, long-term follow-up study of unilateral MRI-guided focused ultrasound (MRgFUS) thalamotomy for essential tremor to date. Read...

Read More

[Insightec in Business Wire] SonALAsense forges ahead with first patient dosing for devastating childhood brain cancer

OAKLAND, Calif.–(BUSINESS WIRE)–Diffuse intrinsic pontine glioma (DIPG) is a rare and deadly pediatric brain cancer with a 2% five-year survival rate. To provide therapeutic options for patients and families, SonALAsense is partnering with clinicians at Children’s National Hospital, Ivy Brain Tumor Center at Barrow Neurological Institute, Phoenix Children’s Hospital and University of California San Francisco (UCSF) Medical Center to conduct a phase 1/2 clinical trial for sonodynamic therapy (SDT). This is the first SDT trial for children. Read...

Read More

[Insightec in PR Newswire] Insightec announces financing up to $200 million to fund continued growth

HAIFA, Israel and MIAMI, Sep. 1, 2022 /PRNewswire/ — Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that it signed a credit facility for up to $200 million with affiliates of existing shareholders Perceptive Advisors and Community Fund. The financing has provided Insightec with $100 million at closing, with an additional $100 million of financing potentially available in tranches through 2024. The credit facility is interest-only for five years and matures on August 31, 2027. Read...

Read More

[Insightec in PR Newswire] Insightec receives FDA IDE approval for prostate cancer comparative study using high intensity focused ultrasound technology

HAIFA, Israel and MIAMI, June 30, 2022 /PRNewswire/ — Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that it has received FDA approval for an investigational device exemption (IDE) for a clinical comparative study of the Exablate Prostate system used to treat diseased prostate tissue. This study will evaluate the safety and efficacy of focal treatment using high intensity focused ultrasound when compared to active surveillance in men living with prostate cancer. Read...

Read More

Latest from Twitter